Find FXa Blocker Edoxaban Tosylate Monohydrate 1229194-11-9, CAS 1229194-11-9, CAS NUMBER 1229194-11-9 on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)
Home > Products > 2012 New Product > Anticoagulant Drug Edoxaban(Tosylate Monohydrate)CAS 1229194-11-9

Anticoagulant Drug Edoxaban(Tosylate Monohydrate)CAS 1229194-11-9

Anticoagulant Drug Edoxaban(Tosylate Monohydrate)CAS 1229194-11-9

    Payment Type: L/C,T/T
    Terms of Trade: FOB,CIF,CPT,CIP
    Min. Order: 1 Kilogram
    Delivery Time: 15 Days
    Packaging: AS REQUIRED
    Productivity: KGS
    Transportation: Ocean,Air
    Place of Origin: CHINA
    Supply Ability: TRUE MANUFACTURER

Basic Info

Model No.: 1229194-11-9

Product Description

Edoxaban tosylate Monohydrate CAS number is 1229194-11-9, developed by Japan Daiichi Sankyo Co., Ltd., was approved by the Ministry of Health and Welfare of Japan on April 22, 2011. The current approved indications are Prevention of venous thromboembolism after major orthopedic surgery, including total knee surgery, total hip joint surgery and hip fracture surgery. In 2012, the first triad company disclosed the results of phase III clinical trials of Edoxaban tosylate Monohydrate for hip replacement patients at the annual meeting of the American Society of Hematology in Orlando, and confirmed that oral The efficacy of Edoxaban tosylate Monohydrate in preventing venous thromboembolism is superior to enoxaparin.
Edoxaban tosylate Monohydrate CAS number 1229194-11-9 is the first oral anticoagulant drug marketed in Japan and was first introduced worldwide. It achieved the purpose of inhibiting thrombosis by selectively, reversibly and directly inhibiting coagulation factor X. Clinical development has proven its good tolerance, oral absorption and anticoagulant activity, and clinical trials in Japan and Taiwan. It was confirmed that Edoxaban tosylate Monohydrate inhibits the efficacy and safety of VTE in patients undergoing lower limb plastic surgery. With the aging of the population and the increase in the incidence of cardiovascular diseases, the demand for anticoagulant drugs is increasing. The direct inhibitor of coagulation factor X is the development trend of anticoagulants. Many of them have been approved for marketing in foreign countries. Benefit more patients. The global market capacity of Factor X inhibitors will increase from approximately $6 billion in 2008 to more than $9 billion in 2014.Edoxaban tosylate Monohydrate CAS 1229194-11-9 is a direct coagulation factor X inhibitor, and coagulation factor X is the main target for the development of a new generation of anticoagulant drugs. His oral administration provides convenience for clinical use; clinical trials have demonstrated that edoxaban is safe and effective against tosylate monohydrate. Therefore,Edoxaban tosylate Monohydrate will have more advantages in the field of anticoagulant drugs and thus obtain more business opportunities.

Edoxaban (tosylate Monohydrate) 1229194-11-9 is a small molecule oral anticoagulant drug that is a clotting factor X (FXa) blocker. During the coagulation process, activated factor X (FXa) activates prothrombin (FII) to become thrombin (FIIa), triggering fibrin formation, thereby forming thrombi. Thus FXa has become a major target point for the development of new generation anticoagulants. Edoxaban has a 104 double higher selectivity for FXa than FIIa , reversible and direct inhibition of FXa to achieve oral thromboprophylaxis. Clinical trials have confirmed that the product can effectively inhibit the patients receiving lower extremity orthopedic surgery complicated with VTE, and safe and reliable.

Thera. Category: Anticoagulant drug

Cas No.: 1229194-11-9

Synonym: edoxaban tosylate hydrate;N1-(5-Chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate;Edoxaban Tosylate Hydrate 1; Edoxaban (tosylate Monohydrate);Edoxaban tosilate;Edoxaban p-toluenesulfonate monohydrate;N-(5-Chloropyridin-2-yl)-N'-((1S,2R,4S)-4-[(dimethyl amino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl)ethanediamide p-toluenesulfonate monohydrate;Ethanediamide, N1-(5-chloro-2-pyridinyl)-N2-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, 4-methylbenzenesulfonate, hydrate;

Molecular Formula: C31H40ClN7O8S2


Molecular Weight: 738.2744

Purity: ≥98.%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Related product:

Edoxaban (tosylate Monohydrate) 1229194-11-9

Edoxaban 912273-65-5

Edoxaban 480449-70-5

Tert-Butyl(1R,2S,5S)-2-azido-5-[(dimethylamino)carbonyl]cyclohexylcarbamate oxalic acid Cas 1353893-22-7

Taizhou Volsen Chemical Co., Ltd.


Taizhou Volsen Chemical Co., Ltd. is professional in R&D, producing and marketing Pharmaceutical raw materials, pharmaceutical intermediates in China. VOLSEN consists of about 100 experienced employees including 3 PhD and 10 Master, and 35000 sqm facilities including research laboratories, kilo lab, pilot plant and full manufacturing plant,

VOLSEN R&D specialists, quality manager and sales with abundance experience make sure products are reliable and service is professional. The producing person inspect every step of the whole process and check up the quality strictly, in order to insure every batch of raw material achieve the standard of EP,CP, JP,BP etc.Matching to the diversified requirements of companies VOLSEN is steadily marching to reach the peaks.

Volsen owns a professional custom synthesis department, with more than 15 senior scientific research chemical personnels who have a graduate degree or above. We also have an independent scientific management system. Our company integrates years of production experiences and talent reserves that forms a strong R&D production capacity, furthermore we could undertake various chemicals customizations from kg to ton relying on the existing production base and equipment.

Manufacturing Unit is equipped with a facility of progressive reeducation of emissions, effluents and discharge of waste material that are known to have a negative impact on the environment. Besides, Laboratory as well as plant is equipped with latest Machinery, Equipments, Technical personnel & Means of communications.

Due to supply of reliable quality, efficient follow up, scheduled delivery and prompt response to any matter, company wins good comments from customers.

We aimed at delivering real business value to our clients. For any interest, pls call on us or email us to get our best services.

Company Info

  • Company Name: Taizhou Volsen Chemical Co., Ltd.
  • Representative: Mr Chen
  • Product/Service: Favipiravir Intermediates , Arbidol Intermediates , Relugolix Intermediates , Vilanterol Intermediates , Remdesivir Intermediates , Umeclidinium Bromide
  • Capital (Million US $): 60000000RMB
  • Year Established: 2002
  • Total Annual Sales Volume (Million US $): Above US$100 Million
  • Export Percentage: 91% - 100%
  • Total Annual Purchase Volume (Million US $): Below US$1 Million
  • No. of Production Lines: 5
  • No. of R&D Staff: 91 -100 People
  • No. of QC Staff: 11 -20 People
  • OEM Services Provided: yes
  • Factory Size (Sq.meters): 30,000-50,000 square meters
  • Factory Location: Dongying Economic Development Zone , Dongying, Shandong,China
  • Contact Person: Ms. Amy Cheng
  • Tel: 86-576-88869393
Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters